These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31249529)

  • 21. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent developments in pricing and reimbursement of medicines in Ireland.
    Barry M; Tilson L
    Expert Rev Pharmacoecon Outcomes Res; 2007 Dec; 7(6):605-11. PubMed ID: 20528322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reimbursement of targeted cancer therapies within 3 different European health care systems.
    Mihajlović J; Dolk C; Tolley K; Simoens S; Postma MJ
    Clin Ther; 2015 Feb; 37(2):474-80. PubMed ID: 25638534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways.
    Inotai A; Kaló Z
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):627-632. PubMed ID: 31810392
    [No Abstract]   [Full Text] [Related]  

  • 26. A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges.
    Vella Bonanno P; Cassar V; Godman B
    Front Pharmacol; 2021; 12():666405. PubMed ID: 34867312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
    Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
    [No Abstract]   [Full Text] [Related]  

  • 28. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Policy Updates on Access to and Affordability of Innovative Medicines in China.
    Liu GG; Wu J; He X; Jiang Y
    Value Health Reg Issues; 2022 Jul; 30():59-66. PubMed ID: 35235902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of budget impact and its relationship with cost-effectiveness in reimbursement decisions on health technologies in the Netherlands.
    Reckers-Droog V; Enzing J; Brouwer W
    Eur J Health Econ; 2024 Feb; ():. PubMed ID: 38411843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan.
    Jirawattanapisal T; Kingkaew P; Lee TJ; Yang MC
    Value Health; 2009; 12 Suppl 3():S4-11. PubMed ID: 20586980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Availability and Accessibility of Orphan Medicinal Products to Patients in Slovakia in the Years 2010-2019.
    Foltanova T; Majernik A; Malikova E; Kosirova S
    Front Pharmacol; 2022; 13():768325. PubMed ID: 35153774
    [No Abstract]   [Full Text] [Related]  

  • 35. Methods for the comparative evaluation of pharmaceuticals.
    Zentner A; Velasco-Garrido M; Busse R
    GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy.
    Scheijmans FEV; Zomers ML; Fadaei S; Onrust MR; van der Graaf R; Delden JJMV; van der Pol WL; van Thiel GJMW
    BMC Health Serv Res; 2022 Nov; 22(1):1320. PubMed ID: 36333803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs.
    Chauca Strand G; Bonander C; Jakobsson N; Johansson N; Svensson M
    ESMO Open; 2022 Oct; 7(5):100569. PubMed ID: 36037568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea.
    Bae EY; Lee EK
    Value Health; 2009; 12 Suppl 3():S36-41. PubMed ID: 20586979
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.